Compare · ABT vs RPRX
ABT vs RPRX
Side-by-side comparison of Abbott Laboratories (ABT) and Royalty Pharma plc (RPRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and RPRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $175.37B, about 5.2x RPRX ($33.50B).
- ABT has been more active in the news (12 items in the past 4 weeks vs 7 for RPRX).
- ABT has more recent analyst coverage (25 ratings vs 12 for RPRX).
- Company
- Abbott Laboratories
- Royalty Pharma plc
- Price
- -
- -
- Market cap
- $175.37B
- $33.50B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 12
- 7
- Recent ratings
- 25
- 12
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 45 marketed therapies and 9 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Latest ABT
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
- Robert W. Baird initiated coverage on Abbott Labs with a new price target
- EVP, GC AND SECRETARY Cushman Elizabeth C. covered exercise/tax liability with 560 units of Common shares without par value, decreasing direct ownership by 1% to 38,013 units (SEC Form 4)
Latest RPRX
- Royalty Pharma declares third quarter 2026 dividend
- Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026
- EVP, Research & Investments Urist Marshall sold $508,454 worth of Class A Ordinary Shares (9,099 units at $55.88) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- EVP & Chairman, Partnering Hite Christopher sold $7,345,471 worth of Class A Ordinary Shares (130,000 units at $56.50) as part of a pre-agreed trading plan, decreasing direct ownership by 43% to 40,000 units (SEC Form 4)
- Director Bassler Bonnie L was granted 689 units of Class A Ordinary Shares, increasing direct ownership by 0.88% to 79,181 units (SEC Form 4)
- EVP, Research & Investments Urist Marshall sold $502,067 worth of Class A Ordinary Shares (9,098 units at $55.18) as part of a pre-agreed trading plan, decreasing direct ownership by 50% to 9,099 units (SEC Form 4)
- EVP & Chairman, Partnering Hite Christopher sold $8,159,277 worth of Class A Ordinary Shares (150,000 units at $54.40) as part of a pre-agreed trading plan (SEC Form 4)
- Director Weatherman Elizabeth H was granted 4,545 units of Class A Ordinary Shares, increasing direct ownership by 53% to 13,103 units (SEC Form 4)
- Director Norden Gregory was granted 4,545 units of Class A Ordinary Shares, increasing direct ownership by 2% to 196,348 units (SEC Form 4)
- Director Love Ted W was granted 4,545 units of Class A Ordinary Shares, increasing direct ownership by 8% to 58,393 units (SEC Form 4)